Gilead Pays $202 Million to Settle HIV Drug Kickback Case Spanning 6 Years

Gilead Sciences will pay $202 million to resolve allegations that it paid unlawful incentives to doctors for prescribing high-cost HIV medications. According to the U.S. Attorney’s Office in Manhattan, the settlement addresses civil claims tied to a years-long scheme that ran from 2011 to 2017.

The biotech giant allegedly funneled funds to physicians through lavish speaking engagements, meals, and travel perks, under the guise of educational programs. These initiatives, while framed as medical outreach, were reportedly used to influence prescribing behavior for drugs such as Biktarvy, Descovy, Stribild, Genvoya, Complera, and Odefsey.

In one case, a single physician received over $300,000 in payments and generated more than $6 million in Medicare charges through prescriptions of Gilead’s HIV treatments.

Prosecutors say the conduct violated the federal Anti-Kickback Statute, ultimately leading to fraudulent reimbursement claims submitted to public health insurance programs like Medicare and Medicaid.

This settlement brings to light the ongoing scrutiny of pharmaceutical marketing tactics and the financial influence they may exert on medical decisions. While Gilead has resolved the civil matter, the case underscores growing government pressure on drugmakers to uphold ethical standards.